See more : IXICO plc (IXI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kwang Dong Pharmaceutical Co., Ltd. (009290.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kwang Dong Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Performance Drink Group, Inc. (PDPG) Income Statement Analysis – Financial Results
- The Hash Corporation (REZNF) Income Statement Analysis – Financial Results
- Aeolus Pharmaceuticals, Inc. (AOLS) Income Statement Analysis – Financial Results
- Kforce Inc. (KFRC) Income Statement Analysis – Financial Results
- The Progressive Corporation (0KOC.L) Income Statement Analysis – Financial Results
Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
About Kwang Dong Pharmaceutical Co., Ltd.
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of antitussive expectorants, ophthalmic, liver disease agents, mineral preparations, vitamins, circulating system, and nutritious tonics; and ETC drugs in the areas of oral hypoglycemic agents, anti-arteriosclerotic agents, metabolic drugs, vitamins, digestive organ agents, circulating systems, immunosuppressants, obesity drugs, urinary genital and anal drugs, appetite suppressants, neuropsychiatric solvents, antispasmodics, antitussive expectorants, anti-vertigo drugs, antivirals agents, anti-malignant-tumor agents, and vasodilator, as well as antiepileptic, antihistaminic, antipyretic, analgesic, and anti-inflammatory agents. The company also provides general supplements, OTC drinks, consumer drinks, functional drinks, and traditional health foods. In addition, it engages in the operation of hospitals; and the retail and wholesale of products through discount stores, TV home shopping, and Internet shopping malls. Further, the company operates as a MRO total service provider for the raw/intermediate materials and consumables under various business models, such as the construction purchase service and overseas local purchase service. Kwang Dong Pharmaceutical Co., Ltd. was founded in 1963 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,514.45B | 1,431.55B | 1,338.18B | 1,243.77B | 1,238.25B | 1,180.22B | 1,141.57B | 1,056.43B | 955.45B | 522.27B | 468.38B | 332.64B | 313.99B | 289.43B | 276.59B | 276.17B | 250.52B |
| Cost of Revenue | 1,219.34B | 1,149.50B | 1,063.93B | 986.06B | 979.59B | 938.63B | 894.46B | 808.72B | 722.81B | 328.24B | 297.95B | 197.03B | 177.28B | 163.00B | 156.61B | 155.62B | 140.36B |
| Gross Profit | 295.12B | 282.05B | 274.25B | 257.71B | 258.67B | 241.59B | 247.11B | 247.71B | 232.64B | 194.03B | 170.43B | 135.61B | 136.71B | 126.43B | 119.97B | 120.56B | 110.16B |
| Gross Profit Ratio | 19.49% | 19.70% | 20.49% | 20.72% | 20.89% | 20.47% | 21.65% | 23.45% | 24.35% | 37.15% | 36.39% | 40.77% | 43.54% | 43.68% | 43.38% | 43.65% | 43.97% |
| Research & Development | 15.27B | 9.68B | 8.32B | 5.96B | 5.34B | 4.18B | 1.51B | 5.03B | 456.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00M | 90.00M |
| General & Administrative | 15.17B | 14.78B | 13.13B | 11.45B | 14.55B | 13.86B | 14.61B | 14.99B | 13.15B | 11.77B | 10.44B | 9.63B | 9.51B | 11.66B | 11.31B | 12.33B | 9.33B |
| Selling & Marketing | 133.10B | 126.13B | 124.11B | 112.80B | 114.29B | 107.51B | 118.46B | 115.73B | 97.74B | 79.52B | 65.55B | 47.37B | 47.19B | 40.74B | 41.52B | 42.43B | 35.91B |
| SG&A | 233.85B | 140.91B | 137.24B | 124.25B | 128.84B | 121.37B | 133.07B | 130.71B | 110.89B | 91.29B | 75.99B | 57.00B | 56.69B | 52.40B | 52.82B | 54.76B | 45.24B |
| Other Expenses | 0.00 | 93.21B | 83.76B | 80.91B | 82.69B | 748.76M | -820.39M | -2.79B | -1.03B | -2.24B | -1.28B | 771.30M | 951.77M | -744.05M | -2.11B | 1.57B | -348.37M |
| Operating Expenses | 249.12B | 243.80B | 229.32B | 211.12B | 216.86B | 207.65B | 211.37B | 203.32B | 181.78B | 143.58B | 126.04B | 99.27B | 96.56B | 88.14B | 87.00B | 90.67B | 79.60B |
| Cost & Expenses | 1,465.69B | 1,393.30B | 1,293.25B | 1,197.18B | 1,196.45B | 1,146.28B | 1,105.83B | 1,012.04B | 904.59B | 471.82B | 424.00B | 296.30B | 273.84B | 251.14B | 243.61B | 246.29B | 219.96B |
| Interest Income | 4.49B | 1.81B | 1.14B | 1.78B | 2.19B | 1.78B | 1.36B | 1.52B | 1.40B | 1.83B | 1.69B | 1.65B | 1.82B | 2.04B | 2.10B | 2.76B | 2.33B |
| Interest Expense | 6.90B | 3.74B | 2.54B | 2.54B | 3.18B | 2.78B | 2.46B | 2.59B | 2.64B | 2.20B | 2.30B | 1.26B | 1.27B | 1.33B | 1.49B | 1.79B | 1.80B |
| Depreciation & Amortization | 12.90B | 13.95B | 14.04B | 19.64B | 18.74B | 17.41B | 15.29B | 14.52B | 11.52B | 7.60B | 7.59B | 7.50B | 5.99B | 6.10B | 7.71B | 8.04B | 8.36B |
| EBITDA | 67.44B | 54.51B | 51.02B | 85.19B | 58.72B | 51.59B | 51.10B | 57.31B | 62.39B | 58.06B | 51.98B | 46.28B | 47.92B | 44.90B | 41.93B | 42.52B | 41.75B |
| EBITDA Ratio | 4.45% | 3.96% | 4.78% | 5.71% | 5.26% | 4.61% | 4.49% | 5.54% | 6.59% | 11.12% | 11.23% | 13.99% | 15.75% | 15.84% | 14.86% | 16.03% | 16.64% |
| Operating Income | 48.77B | 38.24B | 44.94B | 46.59B | 41.80B | 33.94B | 35.74B | 44.39B | 50.87B | 50.46B | 44.39B | 36.34B | 38.61B | 38.30B | 32.97B | 29.89B | 30.56B |
| Operating Income Ratio | 3.22% | 2.67% | 3.36% | 3.75% | 3.38% | 2.88% | 3.13% | 4.20% | 5.32% | 9.66% | 9.48% | 10.92% | 12.30% | 13.23% | 11.92% | 10.82% | 12.20% |
| Total Other Income/Expenses | 251.69M | -8.38B | -10.61B | 8.49B | -5.03B | -2.55B | -2.39B | -4.20B | -1.08B | -2.11B | -4.52B | 1.18B | 2.05B | -824.15M | -246.32M | 2.81B | 1.03B |
| Income Before Tax | 49.02B | 36.29B | 34.33B | 62.95B | 36.77B | 31.40B | 33.35B | 40.19B | 49.72B | 47.35B | 39.83B | 37.52B | 40.67B | 37.48B | 32.73B | 32.69B | 31.59B |
| Income Before Tax Ratio | 3.24% | 2.54% | 2.57% | 5.06% | 2.97% | 2.66% | 2.92% | 3.80% | 5.20% | 9.07% | 8.50% | 11.28% | 12.95% | 12.95% | 11.83% | 11.84% | 12.61% |
| Income Tax Expense | 9.65B | 9.59B | 8.79B | 17.35B | 14.11B | 9.42B | 10.27B | 12.29B | 13.63B | 12.29B | 17.83B | 9.76B | 10.77B | 12.26B | 9.54B | 11.28B | 7.43B |
| Net Income | 36.97B | 24.17B | 24.02B | 45.37B | 23.06B | 22.35B | 23.20B | 28.06B | 35.02B | 35.04B | 22.04B | 27.82B | 29.92B | 25.21B | 23.19B | 21.41B | 24.16B |
| Net Income Ratio | 2.44% | 1.69% | 1.79% | 3.65% | 1.86% | 1.89% | 2.03% | 2.66% | 3.66% | 6.71% | 4.70% | 8.36% | 9.53% | 8.71% | 8.38% | 7.75% | 9.64% |
| EPS | 913.39 | 588.45 | 584.68 | 1.12K | 581.72 | 551.00 | 572.00 | 692.00 | 868.00 | 869.00 | 538.00 | 668.00 | 683.00 | 552.00 | 497.00 | 447.00 | 489.00 |
| EPS Diluted | 913.39 | 588.45 | 584.33 | 1.12K | 581.72 | 551.00 | 572.00 | 692.00 | 868.00 | 869.00 | 538.00 | 668.00 | 683.00 | 552.00 | 497.00 | 447.00 | 489.00 |
| Weighted Avg Shares Out | 40.47M | 41.08M | 41.08M | 40.53M | 39.64M | 40.55M | 40.55M | 40.55M | 40.34M | 40.33M | 40.96M | 41.65M | 43.81M | 45.68M | 46.65M | 47.89M | 49.41M |
| Weighted Avg Shares Out (Dil) | 40.47M | 41.08M | 41.13M | 40.53M | 39.64M | 40.55M | 40.55M | 40.55M | 40.34M | 40.33M | 40.96M | 41.65M | 43.81M | 45.68M | 46.65M | 47.89M | 49.41M |
Source: https://incomestatements.info
Category: Stock Reports